Symptomatic Pharmacotherapy in ALS: Data Analysis from a Platform-Based Medication Management Programme

Total Page:16

File Type:pdf, Size:1020Kb

Symptomatic Pharmacotherapy in ALS: Data Analysis from a Platform-Based Medication Management Programme PostScript J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2020-322938 on 21 April 2020. Downloaded from LETTER during the observation. Riluzole was ALS were provided with a mean number the drug most commonly used (93% of 3.2 symptomatic drugs. However, of patients; n=2219). Symptomatic the number of drugs per patient varied Symptomatic pharmacotherapy drugs were assorted to pharmacological substantially (figure 1D). Furthermore, in ALS: data analysis from a domains and to the attainment of treat- we identified an increasing number of ment goals (figure 1B). An overview prescribed drugs per patient in correla- platform- based medication and ranking of symptomatic drugs are tion to advanced stages of King’s clinical management programme summarised in the online supplementary stages of ALS (figure 1C).4 file 2. Based on the number of patients who received the drug, the following top INTRODUCTION 10 symptomatic medicines were identi- DISCUSSION Although symptomatic medicines fied (in decreasing order): mirtazapine, The symptomatic medication was anal- constitute an important intervention ipratropium bromide, pirenzepine, ysed at specialised ALS centres in in amyotrophic lateral sclerosis (ALS), citalopram, lorazepam, baclofen, metam- Germany collaborating on multidisci- few systematic investigations into drug izole, quinine, fentanyl and tetrahydro- plinary managed care. Data assessment management have been reported so far.1 cannabinol:cannabidiol. Patients with was facilitated by the common use of Furthermore, symptomatic pharmaco- therapy is constantly evolving with an increasing number of drugs being used. Therefore, more detailed information on drug prescription must be obtained to monitor the current standards of care, identify potential shortcomings in drug management and elucidate progress in symptomatic pharmacotherapy. Thus, the aims of the present study were to (i) identify the spectrum of symptom- atic drugs; (ii) rank symptomatic drugs according to their frequency of use; (iii) assign symptomatic drugs to pharmaco- logical domains and (iv) determine the number of symptomatic drugs per patient. We hypothesised that the pharmacolog- ical spectrum and frequency of use range widely. Furthermore, we supposed that symptomatic drug treatment may vary substantially among patients with ALS and may be highly personalised. http://jnnp.bmj.com/ METHODS A prospective, multicentre, cross- sectional observational study was conducted. The Figure 1 (A) Characteristics of the study participants. (B) Assignment of symptomatic drugs to participants met the following criteria: (1) pharmacologic domains and ranking according to the frequency of use. The number and percentage 2 diagnosis of ALS ; (2) one or more ALS- of patients is shown who received the drug during the course of ALS treatment. Symptomatic drugs related drug prescriptions; (3) participa- were assorted the leading domains of symptomatic drugs: (1) anticholinergic drugs: pirenzepine, tion in a case management programme ipratropium bromide, amitriptyline, atropine, scopolamine, bornaprine, (2) antidepressant drugs: on October 1, 2021 by guest. Protected copyright. for ALS medication; (4) consent to data mirtazapine, citalopram, amitriptyline, escitalopram, opipramol, dextromethorphan/quinidine, 3 capture using a digital research platform. agomelatine, venlafaxine, sertraline, trimipramine, duloxetine, paroxetine; (3) antispasmodic drugs: The cohort encompassed patients who had baclofen, tetrahydrocannabinol:cannabidiol, tizanidine, 4- aminopyridine, botulinum toxin, tolperisone; received treatment at nine specialised ALS (4) benzodiazepines: lorazepam, diazepam; (5) non- opioid analgesic drugs: metamizole, ibuprofen, centres in Germany between July 2013 diclofenac, etoricoxib; (6) opioid drugs: fentanyl, oxycodone, tilidine, tramadol, morphine sulfate, and December 2019. Participant’s demo- tapentadol, tramadol, codeine; (7) cramp- reducing drugs: quinine; (8) hypnotic drugs: zopiclone, graphic and clinical data are summarised zolpidem, melatonin; (9) anticonvulsant drugs: pregabalin, gabapentin, carbamazepine; (10) in figure 1A. Detailed methods and the prokinetic and laxative drugs: polyethylene glycol, domeridone, metoclopramide; (11) Parkinson setting of the study are listed in the online drugs: levodopa, rotigotine, pramipexol, ropinirole; (12) broncholytic drugs: acetylcysteine, tyloxapol, supplementary file 1. carbomer, salbutamol, ambroxol; (13) psycholeptic drugs: olanzapine, quetiapine, melperone; (14) overactive bladder drugs: oxybutynin, trospium, butylscopolamine; (15) cholinergic drugs: pyridostigmine. (C) Number of symptomatic drugs per patient in relation to the King’s clinical stage RESULTS of ALS; stage 1=involvement of one clinical region; stage 2=involvement of second clinical region; A cohort of 2392 patients with ALS stage 3=involvement of third clinical region; stage 4=nutritional or respiratory failure. (D) Number of including 7562 prescriptions of ALS- symptomatic drugs per patient. The number of drugs per patient referred to all drugs of any given related medicines was captured. A total patient that were applied during the course of disease. Detailed methods are listed in the online of 1157 patients (48.4%) had died supplementary file 1. n, number of patients; SD, standard deviation. J Neurol Neurosurg Psychiatry July 2020 Vol 91 No 7 783 PostScript J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2020-322938 on 21 April 2020. Downloaded from a digital management platform that the national variability in legal and social 8Department of Neurology, Technische Universität Dresden, Dresden, Germany allowed for an assessment of ALS phar- frameworks of drug treatment. 9 macotherapy in the largest cohort so far. The high number of medicines per Research Site Dresden, DZNE, German Center for Neurodegenerative Diseases, Dresden, Germany Moreover, this study included patients at patient (mean 3.2 drugs) underlines the 10Department of Neurology, Hannover Medical School, all stages of the disease. In contrast, symp- relevance of symptomatic pharmaco- Hannover, Germany tomatic drugs were previously collected therapy. One fifth of patients requested 11Department of Neurology, University of Ulm, Ulm, in the context of clinical trials or in late- more than four symptomatic drugs. Germany stage ALS.5 6 In this study, we identified The actual frequency of prescriptions Correspondence to Professor Thomas Meyer, about 100 different drugs administered may even higher as some symptomatic Department of Neurology, Center for ALS and other for symptomatic treatment in ALS. This drugs are likely to have been prescribed Motor Neuron Disorders, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany; thomas. meyer@ charite. impressive number may give rise to the outside the platform. Strikingly, the de conclusion that symptomatic pharmaco- number of drugs requested per patient Acknowledgements The authors wish to thank the therapy is highly diverse and variable, ranged widely (range 1 drug to 18 medi- Boris Canessa ALS Stiftung (Düsseldorf), ’Initiative für supposedly an underestimated fact. The cines). Such variability may be due to Menschen mit ALS’ (Berlin) and Bremer ALS Stiftung ranking of drugs revealed striking differ- the different stages of ALS covered with (Bremen), for co- funding this work and for their ences in the frequency of use ranging from this cohort. In fact, the finding of an continuous support. frequently used to rarely applied agents. increasing number of drugs per patient in Contributors TM: contributed to the design, The highest- ranking drugs encompassed advanced stages of King’s clinical stages conceptualisation, writing, data analysis, data agents for the treatment of excessive of ALS is contributing to this notion acquisition and critical revision of the manuscript. DK, AM, TG, UW, JG, RS, JN, AG, AH, RG, SP, OS, JD salivation, depression and/or emotional (figure 1C, online supplementary file 3). and AL: contributed to the data acquisition and lability, spasticity, anxiety, moderate pain Further investigations are of interest to critical revision of the manuscript. BW: contributed and severe pain or dyspnoea, and fascic- correlate classes of symptomatic medi- to the statistical analysis, data analysis and critical ulations (online supplementary file 2). By cines (and distinct drugs) to stages of revision of the manuscript. CM: contributed to the allocating symptomatic drugs to pharma- design, conceptualisation and critical revision of the disease (or to specific symptoms). manuscript. SS: contributed to the writing, statistical cological domains, it becomes even clearer In conclusion, symptomatic drug treat- analysis, data analysis and critical revision of the how these drugs rank (figure 1B). ment was a frequent and ongoing health- manuscript. The data on symptomatic drugs care intervention in the cohort studied. Competing interests TM and CM are founders as prescribed by ALS specialists are Pharmacotherapy in ALS was complex, of the digital management platform ’APST’ and hold intended to provide a broad benchmark individualised and included multiple shares in Ambulanzpartner Soziotechnologie APST of ALS drug management. It may offer drugs. Despite its pivotal importance to GmbH. support to neurologists and other physi- ALS care, for most of the many symp- Patient consent for publication Not required. cians who seek guidance in symptomatic tomatic drugs, the level of evidence Ethics approval Ethical approval
Recommended publications
  • Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD
    Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD April 2015 CONTENTS General Toxicology 9 Metals 44 Management 22 Pesticides 49 Drugs 23 Chemical Warfare 51 Chemical Incidents & 36 Plants 52 Pollution Chemicals 37 Animals 52 CURRENT AWARENESS PAPERS OF THE MONTH Acute toxicity profile of tolperisone in overdose: observational poison centre-based study Martos V, Hofer KE, Rauber-Lüthy C, Schenk-Jaeger KM, Kupferschmidt H, Ceschi A. Clin Toxicol 2015; online early: doi: 10.3109/15563650.2015.1022896: Introduction Tolperisone is a centrally acting muscle relaxant that acts by blocking voltage-gated sodium and calcium channels. There is a lack of information on the clinical features of tolperisone poisoning in the literature. The aim of this study was to investigate the demographics, circumstances and clinical features of acute overdoses with tolperisone. Methods An observational study of acute overdoses of tolperisone, either alone or in combination with one non-steroidal anti-inflammatory drug in a dose range not expected to cause central nervous system effects, in adults and children (< 16 years), reported to our poison centre between 1995 and 2013. Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units. The NPIS is commissioned by Public Health England Results 75 cases were included: 51 females (68%) and 24 males (32%); 45 adults (60%) and 30 children (40%). Six adults (13%) and 17 children (57%) remained asymptomatic, and mild symptoms were seen in 25 adults (56%) and 10 children (33%).
    [Show full text]
  • Clinical Manifestation of Juvenile and Pediatric HD Patients: a Retrospective Case Series
    brain sciences Article Clinical Manifestation of Juvenile and Pediatric HD Patients: A Retrospective Case Series 1, , 2, 2 1 Jannis Achenbach * y, Charlotte Thiels y, Thomas Lücke and Carsten Saft 1 Department of Neurology, Huntington Centre North Rhine-Westphalia, St. Josef-Hospital Bochum, Ruhr-University Bochum, 44791 Bochum, Germany; [email protected] 2 Department of Neuropaediatrics and Social Paediatrics, University Children’s Hospital, Ruhr-University Bochum, 44791 Bochum, Germany; [email protected] (C.T.); [email protected] (T.L.) * Correspondence: [email protected] These two authors contribute to this paper equally. y Received: 30 April 2020; Accepted: 1 June 2020; Published: 3 June 2020 Abstract: Background: Studies on the clinical manifestation and course of disease in children suffering from Huntington’s disease (HD) are rare. Case reports of juvenile HD (onset 20 years) describe ≤ heterogeneous motoric and non-motoric symptoms, often accompanied with a delay in diagnosis. We aimed to describe this rare group of patients, especially with regard to socio-medical aspects and individual or common treatment strategies. In addition, we differentiated between juvenile and the recently defined pediatric HD population (onset < 18 years). Methods: Out of 2593 individual HD patients treated within the last 25 years in the Huntington Centre, North Rhine-Westphalia (NRW), 32 subjects were analyzed with an early onset younger than 21 years (1.23%, juvenile) and 18 of them younger than 18 years of age (0.69%, pediatric). Results: Beside a high degree of school problems, irritability or aggressive behavior (62.5% of pediatric and 31.2% of juvenile cases), serious problems concerning the social and family background were reported in 25% of the pediatric cohort.
    [Show full text]
  • Clinical Trial Protocol: 201
    Protocol: 201 Amendment 1 Neurana Pharmaceuticals, Inc. 02 May 2019 version 2.0 Confidential CLINICAL TRIAL PROTOCOL: 201 Title: Dose Ranging Study of Tolperisone in Acute Muscle Spasm of the Back, “STAR Study” Substance Tolperisone hydrochloride Identifier IND number 069169 Protocol Number 201 Sponsor Neurana Pharmaceuticals, Inc. 4370 La Jolla Village Drive, Suite 860 San Diego, CA 92122 Date of Protocol 02 MAY 2019 version Amendment # 2.0 1 Previous protocol 15Nov2018, version 1.0 (initial protocol) Sponsor Tom Wessel, M.D. Representative Chief Medical Officer Neurana Pharmaceuticals, Inc. Conduct: In accordance with the ethical principles that originate from the Declaration of Helsinki and that are consistent with International Council for Harmonisation Guidelines on Good Clinical Practice (ICH E6 GCP) and regulatory requirements as applicable Confidentiality Statement The present protocol is the sole property of Neurana Pharmaceuticals, Inc. and it may not in full or in part be passed on, reproduced, published or otherwise disclosed without the express permission of Neurana Pharmaceuticals, Inc. Page 1 of 60 Protocol: 201 Amendment 1 Neurana Pharmaceuticals, Inc. 02 May 2019 version 2.0 Confidential 1.2. Principal Investigator (PI) – Amendment 1 I have read and understand the contents of this clinical protocol 201, the STAR Study, and will adhere to the study requirements as presented, including all statements regarding confidentiality. In addition, I will conduct the study in accordance with current International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice and applicable regulatory requirements: PI SIGNATURE DATE (DD/MMM/YYYY) PRINTED NAME ____________________________________________ Page 3 of 60 Protocol: 201 Amendment 1 Neurana Pharmaceuticals, Inc.
    [Show full text]
  • Spectrophotometric Method for Simultaneous
    Hariyani Kaushik P et al. IRJP 2012, 3 (9) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 – 8407 Research Article SPECTROPHOTOMETRIC METHOD FOR SIMULTANEOUS ESTIMATION OF TOLPERISONE HYDROCHLORIDE AND DICLOFENAC SODIUM IN SYNTHETIC MIXTURE Patel Satish A, Hariyani Kaushik P* Department of Quality Assurance, Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Ganpat Vidyanagar – 384012, Mehsana, Gujarat, India Article Received on: 19/07/12 Revised on: 22/08/12 Approved for publication: 04/09/12 *Email: [email protected] ABSTRACT The present manuscript describes simple, sensitive, rapid, accurate, precise and economical spectrophotometric method for the simultaneous determination of Diclofenac sodium and Tolperisone hydrochloride in bulk and synthetic mixture. The method is based on the simultaneous equations for analysis of both the drugs using methanol as solvent. Diclofenac sodium has absorbance maxima at 281 nm and Tolperisone hydrochloride has absorbance maxima at 255 nm in methanol. The linearity was obtained in the concentration range of 2-20 μg/ml and 2-20 μg/ml for Diclofenac sodium and Tolperisone hydrochloride, respectively. The concentrations of the drugs were determined by using simultaneous equations at both the wavelengths. The mean recovery was 100.6 ± 0.41 and 99.64 ± 0.50 for Diclofenac sodium and Tolperisone hydrochloride, respectively. The method was successfully applied to laboratory prepared synthetic mixture because no interference from the mixture excipients was found. The suitability of this method for the quantitative determination of Diclofenac sodium and Tolperisone hydrochloride was proved by validation. The proposed method was found to be simple and sensitive for the routine quality control application of Diclofenac sodium and Tolperisone hydrochloride in combination.
    [Show full text]
  • Development and Validation of Novel Rp-Hplc Method for Simultaneous Estimation of Gabapentin and Amitriptyline Hydrochloride in Bulk and Pharmaceutical Dosage Forms
    International Journal of Applied Pharmaceutics ISSN- 0975-7058 Vol 10, Issue 2, 2018 Original Article DEVELOPMENT AND VALIDATION OF NOVEL RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF GABAPENTIN AND AMITRIPTYLINE HYDROCHLORIDE IN BULK AND PHARMACEUTICAL DOSAGE FORMS SULTANA SHAIKH 1*, VANDANA JAIN 2 1M. PHARM Student, Department of Quality Assurance, Oriental College of Pharmacy, Sanpada-Navi Mumbai, Maharashtra 400705, 2Department of Quality Assurance, Oriental College of Pharmacy, Sanpada-Navi Mumbai, Maharashtra 400705 Email: [email protected] Received: 18 Jan 2018, Revised and Accepted: 13 Feb 2018 ABSTRACT Objective: To develop a novel, accurate, precise and linear reverse phase high performance liquid chromatographic (RP-HPLC) method for simultaneous quantitative estimation of gabapentin and amitriptyline hydrochloride in gabantip-at tablet and validate as per international conference on harmonization (ICH) guidelines and to perform the force degradation studies using the developed method. Methods: In the present work, good chromatographic separation was achieved isocratically using a shim-pack HPLC C18 column (4.6 x 250 mm, 5μm) and mobile phase consisting of 0.05 M potassium dihydrogen orthophosphate pH 2.1 adjusted with orthophosphoric acid and acetonitrile in the ratio (55:45), at flow rate 1 ml/min and column temperature (25 °C). The effluents obtained were monitored at 221 nm with the UV-visible detector. Results: The retention time of gabapentin and amitriptyline hydrochloride was found to be 1.959 min and 4.221 min respectively. The linearity of gabapentin was found in the range of 720-1680 ppm and that for amitriptyline hydrochloride was found to be 24-56 ppm. The correlation coefficient for gabapentin and amitriptyline hydrochloride were 0.999 and 0.9963 respectively.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • WO 2016/074683 Al 19 May 2016 (19.05.2016) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/074683 Al 19 May 2016 (19.05.2016) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/10 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/DK20 15/050343 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 11 November 2015 ( 11. 1 1.2015) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2014 00655 11 November 2014 ( 11. 1 1.2014) DK (84) Designated States (unless otherwise indicated, for every 62/077,933 11 November 2014 ( 11. 11.2014) US kind of regional protection available): ARIPO (BW, GH, 62/202,3 18 7 August 2015 (07.08.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: LUNDORF PEDERSEN MATERIALS APS TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [DK/DK]; Nordvej 16 B, Himmelev, DK-4000 Roskilde DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (DK).
    [Show full text]
  • Designation of Pharmaceuticals Required Securing
    Designation of Pharmaceuticals Required securing Pharmaceutical Equivalence Ministry of Food & Drug Safety Notification No. 2014- 189 (Nov. 26, 2014, Amended) Article 1 (Purpose) In accordance with Article 31(2) and 42(1) of the 「Pharmaceutical Affairs Act」, Articles 4(1)(3) of the 「Regulation on Safety of Medicinal Products, etc.」 and Article 57 of the 「Narcotics Control Act.」, the purpose of this Notification is to set forth the appropriate standards for Pharmaceuticals approval by providing for designates pharmaceuticals required to submit bioequivalence study results and comparative clinical study results, and also designates pharmaceuticals required to submit test results of not using biological matters such as comparative dissolution test in the approval of pharmaceutical manufacturing/marketing and import. Article 2 (Designation of pharmaceuticals requiring pharmaceuticals equivalence test) ① In accordance with Article 4(1)(3)(b) of the 「Regulation on Safety of Medicinal Products, etc..」, Tablets, capsules, or suppository of which ingredients are the same as previously approved pharmaceuticals for manufacturing/marketing and import, are one of the following subparagraph. 1. Conventional pharmaceuticals, their salts and derivatives comprised of a single active pharmaceutical ingredient as listed in the attached Table 1, which are determined by the claim quantity of medical expense of health insurance submitted to the President of Health Insurance Review and Assessment Service by the healthcare institutions as described in Article 43 of the 「National Health Insurance Act」. 2. Expensive pharmaceuticals, their salts and derivatives comprise of a single active pharmaceutical ingredient as listed in the attached Table 2, which are determined by the invoiced amounts of medical expense of health insurance divided by the claim quantity submitted to the President of Health Insurance Review and Assessment Service by the healthcare institutions as described in Article 43 of the 「National Health Insurance Act」.
    [Show full text]
  • Drug Class Review on Skeletal Muscle Relaxants
    Drug Class Review on Skeletal Muscle Relaxants Final Report Update 2 May 2005 Original Report Date: April 2003 Update 1 Report Date: January 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2005 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically (see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 2 Drug Effectiveness Review Project TABLE OF CONTENTS Introduction........................................................................................................................4 Scope and
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]